Home - BioPharma Advisory

Innovation in healthcare is driven globally by drug development for new therapies, use of Big Data applications and progress in medical technologies. For best of success, good science needs to be paired with industry expertise and a robust international network to mitigate clinical, regulatory risk, and accelerate commercialization.
A successful market entry and reduced time-to-market are closely connected to getting the right partners on board at the right time.
Optimized processes, long-term financial planning, company building, and a deep understanding of industry dynamics, players, and developments allows to align the interests of management teams and investors.

Strategy Advice

Business Plan – Company Building and Product Strategy
Clinical Development, Commercialization, Market Entry
Partnering, Licensing
Financial Planning, Fundraising, Transaction Management
Turnaround
Interimsmanagement

Investment Advice

Deal Sourcing
Due Diligence / Valuation
Shareholder structure
Transaction Advice and Management
Shareholder Representation on Supervisory Boards

Alexandra Goll, PhD, nat. Sc., Managing Director

Dr. Alexandra Goll holds vast managerial and operational experience in the international pharmaceutical and biotechnology industry. She took responsibility as a general partner at TVM Capital Life Science in 1998, a specialized life science and biotechnology venture capital fund, overseeing and managing the strategic investment decisions, the investment process, deal structuring and exits until the year 2018. She is a jury member at the Deutscher Zukunftspreis and was jury member at the Fraunhofer Preis (2016-2019).

She took entrepreneurial responsibility serving in selected boards of private and public portfolio companies in Europe and the USA. She resumed responsibility of strategic development, advising with deep industry insight and leveraging her robust international network. She advised and led company building, financings, IPOs, partnering and licensing programs.

She initiated various lead investments proving a sense for outstanding business opportunities by investing in Actelion Ltd., Idenix Pharmaceuticals, Inc., partially sold to Novartis, and Pharmasset Inc. sold to Gilead Sciences, EUSA Pharma Ltd., sold to Jazz Pharmaceuticals Inc., amongst others.

She started her professional career as Global Business Leader for HIV and CMV, responsible for strategic marketing and business development for Virology at Roche. in Basel. She was involved in the clinical development and managing of commercialization strategies of Neupogen® (under an agreement with Amgen), Hivid®, Cymevene® and Valcyte®.

Alexandra Goll holds a degree in pharmacy from the Free University of Berlin and wrote her doctoral dissertation in natural sciences at Philipps University of Marburg. She was honored with a post-doctoral position supported by the Boehringer-Ingelheim Foundation for fundamental research in medicine. Alexandra is a qualified supervisory board member certified by Deutsche Börse.

She was a columnist for German VC Magazin and was elected one of Europe’s 40 most influential Private Equity and Venture Capital managers by industry voice Private Equity News in 2008.